| Maria N Bergstrand, MD | |
|
5435 Feltl Rd, Minnetonka, MN 55343-7983 | |
| (952) 835-9880 | |
| Not Available |
| Full Name | Maria N Bergstrand |
|---|---|
| Gender | Female |
| Speciality | Emergency Medicine |
| Location | 5435 Feltl Rd, Minnetonka, Minnesota |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144634841 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 61843 (Minnesota) | Primary |
| Entity Name | Emergency Physicians Professional Association |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801871934 PECOS PAC ID: 9537072657 Enrollment ID: O20031106000068 |
News Archive
A Ludwig Cancer Research study has uncovered a novel vulnerability in tumors that are driven by a common cancer gene known as MYC. Such cancers, it found, are highly dependent on the cell's machinery for making fats and other lipids.
Announcing a new article publication for BIO Integration journal. In this review article the authors Yue Li, Zhiyi Chen and Shuping Ge from First Affiliated Hospital of University of South China, Hengyang, China and Tower Health and Drexel University, Philadelphia, PA, USA summarize current state of the art applications of microbubble-cell interactions and sonoporation effects to cellular functions.
Gene therapy can safely rebuild the immune systems of older children and young adults with X-linked severe combined immunodeficiency (SCID-X1), a rare inherited disorder that primarily affects males, scientists from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, have found.
Reporting of radiation therapy details in randomized controlled trials for Hodgkin's and non-Hodgkin's lymphoma is deficient due to a lack of reporting of key radiation therapy descriptors and quality assurance processes designed to ensure the accuracy and reproducibility of treatment regimens, according to a February 1 study in the International Journal of Radiation Oncology*Biology*Physics, the official journal of the American Society for Radiation Oncology.
Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced topline results from a Phase II clinical trial conducted by Roche and Genentech, Curis' collaborator and a wholly owned member of the Roche Group, of GDC-0449, a first-in-class Hedgehog pathway inhibitor. GDC-0449 was tested in combination with Avastin® (bevacizumab) and FOLFOX or FOLFIRI chemotherapy in first-line metastatic colorectal cancer patients.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Maria N Bergstrand, MD 5435 Feltl Road, Minnetonka, MN 55343-7983 Ph: (952) 835-9880 | Maria N Bergstrand, MD 5435 Feltl Rd, Minnetonka, MN 55343-7983 Ph: (952) 835-9880 |
News Archive
A Ludwig Cancer Research study has uncovered a novel vulnerability in tumors that are driven by a common cancer gene known as MYC. Such cancers, it found, are highly dependent on the cell's machinery for making fats and other lipids.
Announcing a new article publication for BIO Integration journal. In this review article the authors Yue Li, Zhiyi Chen and Shuping Ge from First Affiliated Hospital of University of South China, Hengyang, China and Tower Health and Drexel University, Philadelphia, PA, USA summarize current state of the art applications of microbubble-cell interactions and sonoporation effects to cellular functions.
Gene therapy can safely rebuild the immune systems of older children and young adults with X-linked severe combined immunodeficiency (SCID-X1), a rare inherited disorder that primarily affects males, scientists from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, have found.
Reporting of radiation therapy details in randomized controlled trials for Hodgkin's and non-Hodgkin's lymphoma is deficient due to a lack of reporting of key radiation therapy descriptors and quality assurance processes designed to ensure the accuracy and reproducibility of treatment regimens, according to a February 1 study in the International Journal of Radiation Oncology*Biology*Physics, the official journal of the American Society for Radiation Oncology.
Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced topline results from a Phase II clinical trial conducted by Roche and Genentech, Curis' collaborator and a wholly owned member of the Roche Group, of GDC-0449, a first-in-class Hedgehog pathway inhibitor. GDC-0449 was tested in combination with Avastin® (bevacizumab) and FOLFOX or FOLFIRI chemotherapy in first-line metastatic colorectal cancer patients.
› Verified 5 days ago
Dr. Kendal Farrar, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 5435 Feltl Rd, Minnetonka, MN 55343 Phone: 952-835-9880 Fax: 952-857-1554 | |
Taj Melson, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 5435 Feltl Rd, Minnetonka, MN 55343 Phone: 952-835-9880 Fax: 952-857-1554 | |
Edgar Austria, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 5435 Feltl Rd, Minnetonka, MN 55343 Phone: 952-857-1154 Fax: 952-857-1154 | |
Justin Matthew Steinberg, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 5435 Feltl Rd, Minnetonka, MN 55343 Phone: 952-835-9880 Fax: 952-857-1554 | |
Arthur James Puff, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 15008 Crown Dr, Minnetonka, MN 55345 Phone: 952-933-9735 | |
Dr. Robert Anderson, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 5435 Feltl Rd, Minnetonka, MN 55343 Phone: 952-835-9880 | |
Dr. Michael Steven Schwemm, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 5435 Feltl Rd, C/o Eppa, Minnetonka, MN 55343 Phone: 952-835-9880 |